| 33.2011 -0.219 (-0.66%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 40.35 |
1-year : | 41.41 |
| Resists | First : | 34.55 |
Second : | 35.45 |
| Pivot price | 34.46 |
|||
| Supports | First : | 33.09 |
Second : | 27.53 |
| MAs | MA(5) : | 33.76 |
MA(20) : | 34.54 |
| MA(100) : | 33.19  |
MA(250) : | 29.67 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 5.6 |
D(3) : | 13.1 |
| RSI | RSI(14): 38.1 |
|||
| 52-week | High : | 35.45 | Low : | 23.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MEDX ] has closed above bottom band by 5.4%. Bollinger Bands are 74.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 33.79 - 34.03 | 34.03 - 34.21 |
| Low: | 32.47 - 32.79 | 32.79 - 33.04 |
| Close: | 32.76 - 33.19 | 33.19 - 33.52 |
The Horizon Kinetics Medical ETF seeks long-term growth of capital by investing primarily in patented first line pharmaceuticals and biologics, aiming to capture returns from intrinsic valuation realization and scientific discovery.
Thu, 12 Mar 2026
(MEDX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Sun, 01 Mar 2026
Liquidity Mapping Around (MEDX) Price Events - Stock Traders Daily
Tue, 24 Feb 2026
Medical ETF (MEDX) Touches New 52-Week High - Yahoo Finance
Tue, 24 Feb 2026
Medical ETF (MEDX) Touches New 52-Week High - Nasdaq
Tue, 21 Oct 2025
Horizon Kinetics Announces Upcoming Horizon Kinetics Active ETF Portfolio Manager Webinar Series - Yahoo Finance
Fri, 08 Aug 2025
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|